Beth Seidenberg, M.D.

Beth Seidenberg, M.D. has served as a member of our board of directors since May 2010 and as Lead Independent Director since January 2022. Previously, Dr. Seidenberg served as Chair of our board of directors from June 2015 to December 2021. Dr. Seidenberg has been a partner at Kleiner Perkins, a venture capital firm, since May 2005, where she primarily focuses on life sciences investing. She has also served as the Managing Director of Westlake Village BioPartners, another venture capital firm, since August 2018. Prior to joining Kleiner Perkins, Dr. Seidenberg was the Senior Vice President, Head of Global Development and Chief Medical Officer at Amgen, Inc., a biotechnology company. In addition, Dr. Seidenberg was a senior executive in research and development at Bristol Myers Squibb Company, a biopharmaceutical company, from March 2000 to December 2001 and Merck & Co., Inc., a healthcare company, from June 1989 to February 2000. Dr. Seidenberg has served on the board of directors of Vera Therapeutics, Inc., a public company, since June 2016, Kyverna Therapeutics, Inc., a public company, since September 2018, Acelyrin since October 2020, and Sagimet since April 2007. Dr. Seidenberg previously served on the board of directors of Epizyme, Inc. from February 2008 to September 2019, Tesaro, Inc. from June 2011 to February 2019, ARMO BioSciences, Inc. from December 2012 to June 2018, RAPT Therapeutics from April 2015 to 2019, and Atara Biotherapeutics from August 2012 to June 2023. Dr. Seidenberg received a B.S. from Barnard College and a M.D. from the University of Miami School of Medicine and completed her post-graduate training at the Johns Hopkins University, George Washington University, and the National Institutes of Health. We believe that Dr. Seidenberg is qualified to serve on our board of directors because of her extensive experience in the life sciences industry as a senior executive and venture capitalist, as well as her training as a physician.